Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Symbicort Renovates Asthma Treatment in Japan: Prof. Adachi
December 21, 2009
- Punishment Proposed by Korosho for Firms That Fail to Develop Requested Drugs
December 21, 2009
- OAB Still Undertreated: Prof. Takahashi
December 21, 2009
- Proposed FY2010 NHI Drug Pricing System Reform (Draft)
December 21, 2009
- Use of Biologics Recommended at Early Stage for RA
December 21, 2009
- Korosho Aims at First Net Increase in Medical Fees in 10 Years
December 21, 2009
- JCR to Verify Acceptability of New ACR/EULAR RA Criteria in Japan
December 21, 2009
- Hospital Market Key to Success of Prasugrel: Mr Shoda
December 21, 2009
- Chuikyo Members Fail to Reach Consensus on Medical Fee Revision Rate
December 21, 2009
- Children with New-Type Flu Not Treated with Tamiflu May Show Abnormal Behavior
December 21, 2009
- Role of DPC Hospitals Needs to Be Reconsidered: Councillor Karasawa
December 21, 2009
- Nippon Shinyaku Submits NDA for Azacitidine for MDS
December 21, 2009
- Chugai to Enter Diabetes Field in Earnest
December 21, 2009
- Banyu Launches Japan's 1st DPP-4 Inhibitor Januvia
December 21, 2009
- Onbrez Breezhaler Approved for COPD in EU: Novartis
December 21, 2009
- GSK to Launch HPV Vaccine Cervarix
December 21, 2009
- Micardis Approved by EC for Reduction in CV Morbidity
December 21, 2009
- Nippon Chemiphar, Ranbaxy Terminate Alliance
December 21, 2009
- Bayer Schering Starts PIII Trial for Florbetaben
December 21, 2009
- Januvia Leaps to Top Place on GP Market: Rep Track Survey
December 21, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…